186 related articles for article (PubMed ID: 37775175)
1. Treatment of hypercalcaemia of malignancy in adults.
Mc Donald D; Drake MT; Crowley RK
Clin Med (Lond); 2023 Sep; 23(5):503-507. PubMed ID: 37775175
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.
El-Hajj Fuleihan G; Clines GA; Hu MI; Marcocci C; Murad MH; Piggott T; Van Poznak C; Wu JY; Drake MT
J Clin Endocrinol Metab; 2023 Feb; 108(3):507-528. PubMed ID: 36545746
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Hypercalcemia of Malignancy.
Chakhtoura M; El-Hajj Fuleihan G
Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
[TBL] [Abstract][Full Text] [Related]
4. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.
Seisa MO; Nayfeh T; Hasan B; Firwana M; Saadi S; Mushannen A; Shah SH; Rajjoub NS; Farah MH; Prokop LJ; Wang Z; Fuleihan GE; Drake MT; Murad MH
J Clin Endocrinol Metab; 2023 Feb; 108(3):585-591. PubMed ID: 36545700
[TBL] [Abstract][Full Text] [Related]
5. Hypercalcemia of Malignancy.
Hu MI
Endocrinol Metab Clin North Am; 2021 Dec; 50(4):721-728. PubMed ID: 34774243
[TBL] [Abstract][Full Text] [Related]
6. [The significance of early diagnosis of cancer-related hypercalcaemia].
Radványi I; Csikós A; Balogh S
Orv Hetil; 2013 Sep; 154(35):1367-73. PubMed ID: 23974972
[TBL] [Abstract][Full Text] [Related]
7. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
8. [Denosumab normalized plasma calcium concentration in malignancy-associated hypercalcaemia].
Størling L; Villadsen GE; Krogh K; Vestergaard P
Ugeskr Laeger; 2014 Jul; 176(30):. PubMed ID: 25292242
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
10. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Hu MI; Glezerman I; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Ying W; Jain RK
J Natl Cancer Inst; 2013 Sep; 105(18):1417-20. PubMed ID: 23990665
[TBL] [Abstract][Full Text] [Related]
11. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
12. Commentary on the endocrine society clinical practice guideline on the "treatment of hypercalcemia of malignancy in adults".
El-Hajj Fuleihan G; Drake MT
Metabolism; 2023 Jun; 143():155553. PubMed ID: 37028591
[No Abstract] [Full Text] [Related]
13. Bisphosphonates and other bone agents for breast cancer.
O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
[TBL] [Abstract][Full Text] [Related]
14. The management of hypercalcaemia in advanced cancer.
Pettifer A; Grant S
Int J Palliat Nurs; 2013 Jul; 19(7):327-31. PubMed ID: 24273809
[TBL] [Abstract][Full Text] [Related]
15. Ectopic parathyroid hormone as a rare aetiology of hypercalcemia with rhabdomyosarcoma: a new treatment strategy with zoledronic acid and Denosumab.
Kilci F; Demirsoy U; Jones JH; Çakır Ö; Çizmecioğlu-Jones FM
J Pediatr Endocrinol Metab; 2022 Aug; 35(8):1107-1112. PubMed ID: 35534911
[TBL] [Abstract][Full Text] [Related]
16. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
McMahan J; Linneman T
Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
[TBL] [Abstract][Full Text] [Related]
17. Denosumab for treatment of hypercalcemia of malignancy.
Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
[TBL] [Abstract][Full Text] [Related]
18. Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma.
Çalapkulu M; Gul OO; Cander S; Ersoy C; Erturk E; Sagiroglu MF; Saraydaroglu O
J Coll Physicians Surg Pak; 2020 Jul; 30(7):757-759. PubMed ID: 32811610
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
20. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
Diel IJ; Body JJ; Stopeck AT; Vadhan-Raj S; Spencer A; Steger G; von Moos R; Goldwasser F; Feng A; Braun A
Eur J Cancer; 2015 Jul; 51(11):1467-75. PubMed ID: 25976743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
